According to Zacks, “National Research Corporation is a leading provider of ongoing survey-based performance measurement, analysis and tracking services to the healthcare industry. The company addresses the growing need of healthcare providers and payers to measure the care outcomes, specifically satisfaction and health status, of their patients and/or members. The company’s primary types of information services are renewable performance tracking services, custom research and a renewable syndicated service. “
National Research Corp. (NASDAQ:NRCIB) traded up 0.99% on Wednesday, reaching $35.60. 1,134 shares of the company’s stock traded hands. The stock’s 50 day moving average is $35.02 and its 200 day moving average is $35.28. The firm has a market cap of $862.27 million, a price-to-earnings ratio of 43.73 and a beta of 0.28. National Research Corp. has a 52-week low of $31.88 and a 52-week high of $44.60.
National Research Corp. (NASDAQ:NRCIB) last posted its quarterly earnings data on Tuesday, August 2nd. The company reported $0.18 earnings per share for the quarter, meeting the consensus estimate of $0.18. National Research Corp. had a net margin of 18.75% and a return on equity of 33.74%. On average, equities research analysts predict that National Research Corp. will post $0.82 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Friday, October 14th. Stockholders of record on Friday, September 30th were given a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a dividend yield of 5.45%. The ex-dividend date of this dividend was Wednesday, September 28th. National Research Corp.’s dividend payout ratio is 408.52%.
In other news, CEO Michael D. Hays sold 3,533 shares of National Research Corp. stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $16.19, for a total transaction of $57,199.27. Following the completion of the sale, the chief executive officer now owns 6,467,744 shares in the company, valued at approximately $104,712,775.36. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 39.09% of the company’s stock.
An institutional investor recently bought a new position in National Research Corp. stock. Willis Investment Counsel acquired a new stake in National Research Corp. (NASDAQ:NRCIB) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,329 shares of the company’s stock, valued at approximately $442,000. Willis Investment Counsel owned 0.06% of National Research Corp. at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.41% of the company’s stock.
National Research Corp. is a business services company in the Health Care Services industry.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for National Research Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research Corp. and related companies with MarketBeat.com's FREE daily email newsletter.